Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq ... “In 2025, we expect important progress across our inhibitor and degrader programs. Our highly selective SMARCA2 ...
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc ...
As the company approaches several key milestones in the second half of 2024, investors and analysts are closely watching its progress in the competitive landscape of oncology and autoimmune treatments ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The continued evolution of treatment protocols and ...
Cartesian Therapeutics (RNAC) highlighted its recent progress and outlined its 2025 strategic priorities across its pipeline of mRNA cell therapy product candidates. Phase 3 AURORA trial of ...
Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00. Farzin Haque has given his Buy rating due to a combination ...
This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics ... Nimbus continues to progress drug discovery efforts across metabolic and autoimmune targets as well, including the ...
Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline progress and anticipated 2025 milestones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results